This is the first study to demonstrate that HIPK1 contributes to pathological cardiac hypertrophy, and that downregulating HIPK1 is beneficial to attenuate pathological hypertrophy, cardiac remodeling, and heart failure. Here, HIPK1 is linked to cardiac hypertrophy.